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Abstract
Background: Leukemia initiating cells (LIC) contribute to therapeutic resistance through acquisition of mutations in
signaling pathways, such as NOTCH1, that promote self-renewal and survival within supportive niches. Activating mutations
in NOTCH1 occur commonly in T cell acute lymphoblastic leukemia (T-ALL) and have been implicated in therapeutic
resistance. However, the cell type and context specific consequences of NOTCH1 activation, its role in human LIC
regeneration, and sensitivity to NOTCH1 inhibition in hematopoietic microenvironments had not been elucidated.
Methodology and Principal Findings: We established humanized bioluminescent T-ALL LIC mouse models transplanted
with pediatric T-ALL samples that were sequenced for NOTCH1 and other common T-ALL mutations. In this study, CD34
+
cells from NOTCH1
Mutated T-ALL samples had higher leukemic engraftment and serial transplantation capacity than
NOTCH1
Wild-type CD34
+ cells in hematopoietic niches, suggesting that self-renewing LIC were enriched within the
NOTCH1
Mutated CD34
+ fraction. Humanized NOTCH1 monoclonal antibody treatment reduced LIC survival and self-renewal in
NOTCH1
Mutated T-ALL LIC-engrafted mice and resulted in depletion of CD34
+CD2
+CD7
+ cells that harbor serial
transplantation capacity.
Conclusions: These results reveal a functional hierarchy within the LIC population based on NOTCH1 activation, which
renders LIC susceptible to targeted NOTCH1 inhibition and highlights the utility of NOTCH1 antibody targeting as a key
component of malignant stem cell eradication strategies.
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Introduction
Seminal research suggests that leukemia relapse occurs because
standard chemotherapy fails to eradicate self-renewing leukemia
initiating cells (LIC) [1–15]. While human myeloid leukemia
xenograft studies demonstrate that LIC reside at the apex of
a cellular hierarchy and are capable of serially transplanting
leukemia [1–3,6], cellular subpopulations within diagnostic pre-
cursor B cell acute lymphoblastic leukemia (ALL) samples
demonstrate greater functional and genetic heterogeneity
[16,17]. Recently, DNA copy number alteration (CNA) profiling
coupled with xenograft analysis suggested that patients with BCR-
ABL1 ALL harboring a predominant clone at diagnosis have
increased rates of early relapse thereby linking LIC clonal
dominance with a poorer prognosis [18].
In another leukemia subtype that is prone to early relapse [19],
pediatric T cell acute lymphoblastic leukemia (T-ALL), serially
transplantable LIC were found to be enriched in CD34
+CD4
2
and CD34
+CD7
2 fractions of newly diagnosed patient samples
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39725[12]. However, these results were obtained after suspension
culture-mediated expansion prior to transplantation potentially
leading to changes in LIC functional capacity. More recently,
a CD7
+CD1a
2 glucocorticoid resistant LIC population, capable
of engrafting leukemia in NOD/SCID IL2Rcnull (NSG) mice,
was identified in primarily adult T-ALL without an in vitro
expansion step [10]. While the LIC population was found to be an
essential driver of therapeutic resistance and relapse, the
NOTCH1 mutational status of the LIC population was not
established; the cell surface phenotype changed during the
prolonged engraftment period and niche dependence of LIC
maintenance, which could ultimately contribute to relapse, was
not elucidated. The high propensity for T-ALL relapse under-
scores the need for LIC characterization based on functional
molecular drivers of survival and self-renewal and spatiotemporal
tracking of niche dependence in bioluminescent serial xenotrans-
plantation models. Together these compelling studies provided the
impetus for investigating the potential LIC propagating capacity of
NOTCH1 mutations, implicated in T-ALL therapeutic resistance
[10] and sensitivity to targeted NOTCH1 inhibition within
selective niches.
While T-ALL represents only 25% of adult and 15% of
pediatric ALL cases, they share an increased risk of early systemic
and isolated central nervous system relapse often in the setting of
mutational NOTCH1 signaling pathway activation [20]. A recent
series of studies showed that NOTCH activation is associated with
improved early therapeutic response (reviewed in [21]). However,
this early benefit translates into improved overall survival only in
some series, most probably as a result of differences in therapy,
and suggests that NOTCH-targeted therapies might represent
promising therapeutic strategies. During normal hematopoiesis,
NOTCH1 regulates cell fate decisions, proliferation and survival
following ligand binding, which triggers a conformational change
in the negative regulatory region (NRR) of the extracellular
domain, enabling juxtamembrane ADAM protease cleavage
[22,23]. Subsequently, c-secretase complex mediated intramem-
brane proteolysis releases an intracellular domain of NOTCH1
(ICN1), which translocates to the nucleus and activates transcrip-
tion of NOTCH target genes [22,24]. In T-ALL, somatic
activating mutations in the NOTCH1 heterodimerization domain
(HD) or PEST domain or alternatively loss-of-function mutations
in FBXW7, a NOTCH1 E3 ubiquitin ligase, increase release or
stability of ICN1. This, in turn, leads to transcriptional activation
of genes that promote proliferation and survival such as MYC and
HES1 [22,24].
Despite a plethora of reports describing mechanisms of
NOTCH1 activation in T-ALL, the cell type and context specific
role of NOTCH1 activation in the maintenance of therapeutically
resistant self-renewing human LIC has not been established. Thus,
we sought to examine (1) whether molecularly characterized LIC
can be identified among specific hematopoietic subpopulations in
pediatric T-ALL without preceding in vitro culture, (2) the role of
NOTCH1 activation in LIC propagation, and (3) whether LIC
have an intrinsic predilection for specific hematopoietic niches.
For these purposes, lentiviral luciferase-transduced CD34-en-
riched (CD34
+) and CD34-depleted (CD34
-) cells from molecu-
larly characterized samples were transplanted into neonatal
RAG2
2/2cc
2/2 mice that permit high levels of human hemato-
poietic engraftment [6,7]. In this study, the CD34
+ fraction of
pediatric NOTCH1
Mutated T-ALL samples had enhanced survival
and self-renewal potential, characteristic of LIC, compared with
their CD34
+ NOTCH1 wild-type (NOTCH1
WT) counterparts.
These NOTCH1
Mutated LIC were uniquely susceptible to targeted
inhibition with a therapeutic human NOTCH1 monoclonal
antibody selective for the NRR (hN1 mAb), while normal
hematopoietic progenitors were spared thereby highlighting the
cell type and context specific effects of NOTCH signaling [13,25–
30] and the importance of oncogenic addiction to NOTCH1
signaling in T-ALL LIC maintenance.
Results
T-ALL Molecular Characterization
Molecular characterization of CD34
+ cells from 12 T-ALL
patient samples was performed by targeted exon sequencing
analysis and focused on genes commonly mutated in T-ALL,
including NOTCH1, PTEN, PIK3R1 and FBXW7 (Table 1).
Selective NOTCH1 DNA sequencing revealed activating muta-
tions in six of eleven newly diagnosed pediatric T-ALL samples
and in one relapsed young adult T-ALL sample (Table 1). In
addition, CD34
+ T-ALL cells derived from these 12 samples were
further sequenced to identify PI3K, PTEN and FBXW7 pathway
mutations common to pediatric T-ALL. Some cases harbored
mutations in PTEN (patients 01, 05, 06, 11) or PIK3R1 (patient
05) genes (Table 1) [31–35]. These data demonstrate that
mutations in NOTCH1 and other genes capable of promoting
LIC survival co-exist in the CD34
+ fraction of T-ALL samples.
NOTCH1
Mutated T-ALL LIC are Serially Transplantable
To determine if lentiviral luciferase-transduced CD34
+ and
CD34
2 cells from NOTCH1
Mutated and NOTCH1
WT pediatric T-
ALL samples differed in their capacity to propagate disease,
quantitative non-invasive bioluminescent imaging was performed
within 10 weeks of intrahepatic transplantation of neonatal
RAG2
2/2cc
2/2 mice (Figures 1A and B). Mice transplanted
with CD34
+ enriched NOTCH1
Mutated T-ALL cells (patients 03, 05,
08, 11) demonstrated significantly greater leukemic engraftment
than mice transplanted with CD34
2 cells (Figures 1B and C;
n=79 mice, P=0.0005, Student’s t-test). Conversely, both CD34
+
and CD34
2 fractions from NOTCH1
WT T-ALL samples (patients
04, 07, 09, 10) exhibited equivalent engraftment capacity in
primary transplant recipients (Figure 1C; n=76 mice). Hence,
CD34
+ cells from NOTCH1
Mutated samples gave rise to higher levels
of bioluminescent engraftment in primary transplant recipients
than their CD34
2 counterparts, indicative of LIC enrichment in
the CD34
+ fraction in NOTCH1
Mutated but not NOTCH1
WT
samples.
The predilection of NOTCH1
Mutated T-ALL LIC for specific
hematopoietic niches was determined in primary and serial
transplants. Primary human NOTCH1
Mutated T-ALL CD34
+ LIC
engraftment was typified by thymic (Figure 1D) and splenic
(Figure 1D) enlargement as well as pale marrow due to
replacement by leukemic cells (Figure 1D). Further analysis
revealed that thymic (P,0.01; Student’s t test) and splenic
(P,0.001, Student’s t-test) weights were significantly greater in
both primary (1u) and secondary (2u) NOTCH1
Mutated T-ALL LIC
transplant recipients than in no transplant control mice (Figures
S1A and B). Moreover, FACS analysis revealed robust CD34
+ cell
engraftment in marrow, spleen and thymus of primary and
secondary NOTCH1
Mutated T-ALL LIC transplanted mice
(Figures 1E and F). CD45
2 cells detected by FACS represent
endogenous mouse cell populations present in the hematopoietic
tissues. Notably, serially transplantable CD34
+ cells from
NOTCH1
Mutated (patients 03, 05, 08, 11) and NOTCH1
High (patient
02) T-ALL samples showed increased human NOTCH1 (***,
P,0.001; **, P,0.01) transcript levels compared to bone marrow
engrafted with NOTCH1
WT (patient 09) CD34
+ T-ALL cells
(Figure S1C). Taken together, these results suggest that
NOTCH1 Inhibition in T-ALL Initiating Cells
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39725NOTCH1-driven LIC have enhanced survival and self-renewal
potential in supportive hematopoietic microenvironments.
hN1 mAb Treatment Reduces NOTCH1
Mutated T-ALL LIC
Survival
The relative leukemic regenerative potential of NOTCH1
Mutated
(Patients 03, 05, 08, 11), and NOTCH1
WT (Patients 04, 07, 09, 10)
samples was determined in serial transplantation studies. FACS
analysis of cells from bone marrow, spleen and thymus showed
that while the levels of thymic engraftment were equivalent,
NOTCH1
Mutated T-ALL LIC gave rise to a significantly higher
CD34
+ leukemic burden in the marrow and spleen of primary
transplant recipients than NOTCH1
WT T-ALL samples (Figures 2A
and B; ***, P,0.001; Student’s t test). Hence, we sought to
determine whether (1) selective NOTCH1 inhibition could reduce
LIC burden, (2) NOTCH1
Mutated T-ALL LIC survival is dependent
on activated NOTCH1 receptor signaling, and (3) selective
NOTCH1 inhibition could spare NOTCH1
WT or normal cord
blood CD34
+ progenitors in engrafted mice. For these purposes,
NOTCH1
Mutated T-ALL LIC-engrafted mice were treated with
a selective NOTCH1-NRR/Fc mAb (hN1 mAb) that specifically
inhibits NOTCH1 receptor signaling (Figures S2A and B).
Animals were treated with hN1 mAb (10 mg/kg) or a control
mouse IgG1 mAb every 4 days for 3 weeks, and over this time
period both antibodies were well-tolerated in treated animals
Figure 1. NOTCH1
Mutated LIC serially transplant T-ALL. (A) Schema of T-ALL LIC mouse model. Equivalent numbers of human CD34
+ and CD34
2
cells derived from both NOTCH1 Mutated (NOTCH1
Mutated and NOTCH1 wild-type (NOTCH1
WT) samples, as defined by DNA sequencing (Table 1),
were selected using immunomagnetic beads from T-ALL blood or bone marrow, transduced with lentiviral luciferase and transplanted (50000 cells/
mouse) intrahepatically into RAG2
2/2cc
2/2 mice within 48 hours of birth. Engraftment was monitored over 10 weeks via non-invasive
bioluminescent imaging system (IVIS 200, Caliper LifeSciences). After 10 weeks, mice were sacrificed and secondary transplants were performed with
50000 immunomagnetically-purified human CD34
+ or CD45
+ cells from primary CD34
+ and CD34
2 T-ALL engrafted mouse marrow, respectively. (B)
T-ALL CD34
+ cells from 12 of 12 T-ALL samples engrafted leukemia to varying extents in the marrow, spleen and thymus in all primary but only 10 of
11 serial transplant recipients. Representative bioluminescent images (captured on an IVIS 200 system) demonstrating engraftment of CD34
+ (50000)
NOTCH1
Mutated T-ALL (1B, upper) compared with an equivalent number of CD34
2 cells (1B, lower). (C) Quantitative bioluminescent imaging (photons/
second/cm
2/sr) of CD34
+ cell and CD34
2 cell engraftment over 10 weeks following transplantation of NOTCH1
Mutated T-ALL samples (red, n=4
patients) compared with NOTCH1
WT samples (blue, n=4 patients). Mice (n=76) transplanted with lentiviral luciferase-transduced NOTCH1
WT patient
samples (Patients 04, 07, 09, 10) and mice (n=79) transplanted with NOTCH1
Mutated patient samples (Patients 03, 05, 08, 11) were included in the
bioluminescent imaging study (error bars, mean 6 SEM. **, P=0.0005, Student’s t-test). (D) Photographs depicting marrow, thymic and splenic size
following NOTCH1
Mutated T-ALL CD34
+ cell (upper panel) and CD34
2 cell (middle panel) transplants compared with no transplant control mice (lower
panel). (E) Representative FACS analysis demonstrating human CD45
+ and CD34
+ leukemic engraftment in the marrow, spleen and thymus in primary
transplant recipients of NOTCH1
Mutated T-ALL Pt 05 CD34
+ cells (CD34
+1u transplant, upper panel) and CD34
2 cells (CD34
2 1u transplant, middle
panel) compared with no transplant control mice (lower panel). (F) Representative FACS analysis demonstrating human CD34
+CD45
+ serial leukemic
engraftment in the marrow (upper), spleen (middle) and thymus (lower) following transplantation of secondary recipients (2u transplant) with 50000
CD34
+ cells isolated from NOTCH1
Mutated T-ALL (Pt 05) primary recipients.
doi:10.1371/journal.pone.0039725.g001
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detectable toxicity (e.g. intestinal) or deleterious effects on survival
in mice, as this antibody does not bind to endogenous murine
NOTCH1 and is expected to only target activity of human
NOTCH1 in transplanted human cells. Following hN1 mAb
treatment of NOTCH1
Mutated T-ALL LIC-transplanted mice, FACS
analysis revealed a significant reduction in leukemic CD34
+ cell
burden in both the marrow and spleen of hN1 mAb-treated mice
(Figure 2C; **, P=0.003 and Figure 2D, ***, P=0.001,
respectively, Wilcoxon test). Levels of CD34
+ cell burden in the
thymus were similar in both groups (Figure 2E), which is likely
a result of relatively lower engraftment rates in this hematopoietic
organ (Figure 2B). Notably, LIC from one T-ALL NOTCH1
Mutated
patient sample (patient 11), with a PTEN frame-shift mutation,
retained sensitivity to hN1 inhibition (Figure 2). While survival of
LIC from a sample (patient 05) with both PTEN and PIK3R1
mutations was not significantly inhibited in the bone marrow, LIC
burden was significantly reduced in the spleen by hN1 mAb
treatment (Figure 2C and D), highlighting the influence of
additional mutations and microenvironmental context in responses
to selective NOTCH1 inhibitory strategies. Although engraftment
rates of normal human cord blood progenitors were low, the
survival of normal CD34
+ hematopoietic progenitors was not
significantly reduced by targeted NOTCH1 inhibition (Figures
S3A and B). These results suggest a greater functional dependence
of NOTCH1
Mutated T-ALL LIC on NOTCH1 signaling in selective
hematopoietic niches compared to NOTCH1
WT progenitors and
normal hematopoietic stem cells (HSC).
Following hN1 mAb treatment, immunohistochemical analy-
ses revealed a marked increase in levels of activated caspase 3,
and a concomitant reduction in levels of NOTCH1 in
NOTCH1
Mutated (patient 08) T-ALL LIC-engrafted bone marrow
compared with control IgG1 mAb-treated control bone marrow
(Figures 3A and B; **, P=0.005; *, P,0.05, Student’s t test).
To assess whether hN1 mAb treatment could inhibit the
generation of transcriptionally active NOTCH1 (intracellular
NOTCH1, ICN1), which may be involved in promoting
therapeutic resistance through induction of self-renewal, ICN1
immunohistochemical analysis was performed on bone marrow
derived from the NOTCH1
Mutated LIC-engrafted mice after
Figure 2. hN1 mAb treatment inhibits NOTCH1
Mutated T-ALL LIC burden. (A) Schema of T-ALL LIC mouse model treatment with a selective
anti-NOTCH1-NRR (hN1) mAb. Within 10 to 12 weeks of NOTCH1
Mutated T-ALL CD34
+ (50000) cell transplantation into post-natal day 2 RAG2
2/2cc
2/2
mice, intraperitoneal treatment was instituted for 3 weeks with a NOTCH1 (hN1, 10 mg/kg every 4 days) mAb or control mAb for 6 doses. Mice were
sacrificed within one day of completion of dosing followed by further studies. (B) The average percentage of CD34
+ engraftment was compared by
FACS analysis of hematopoietic tissues (bone marrow, spleen and thymus) from mice that received transplants of T-ALL LIC from NOTCH1
Mutated
patient samples (03, 05, 08, 11; n=29 mice) and NOTCH1
WT patient samples (04, 06, 09, 10; n=22 mice) (error bars 6 SEM. ***, P,0.001, unequal
variance Student’s t-test). (C) The average percentage of human CD34
+ T-ALL LIC burden in the bone marrow (red, Patient 05, n=6; blue, Patient 08,
n=7; green, Patient 11, n=6) in control mAb treated mice (n=19) and hN1 mAb treated mice (red, Patient 05, n=7; blue, Patient 08, n=7; green,
Patient 11, n=7) (**, P=0.003 by Wilcoxon test) was compared by FACS analysis. Response in the bone marrow of mice transplanted with LIC from
patients 05, 08 and 11 varied (Patient 05, P=0.8308; Patient 08, P=0.007; Patient 11, P=0.017, by Wilcoxon test). In addition to NOTCH1 activating
mutations, patient 05 harbored both PTEN and PI3KR1 mutations and patient 11 had a PTEN frameshift mutation, while patient 08 was wild-type at
these loci (Table 1). (D) Average percentage of T-ALL CD34
+ LIC burden in the mouse spleens following control mAb treatment (n=19) compared to
hN1 mAb treatment (n=21) (***, P,0.001, Wilcoxon test). (E) Average percentage of T-ALL CD34
+ LIC burden in the mouse thymus after control mAb
treatment (n=19) when compared to hN1 mAb treatment (n=21) (no significant differences between the two groups). All results reflect data
collected from two independent experiments.
doi:10.1371/journal.pone.0039725.g002
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with the hN1 mAb was associated with a reduction in bone
marrow ICN1 levels (Figure 3C). These data corroborate that
the antibody’s mechanism of action involves both interference
with ligand binding (Figure S2B) and reduced human
NOTCH1 cleavage and ICN1 generation (Figure 3C).
Strikingly, qRT-PCR analysis demonstrated a significant re-
duction in NOTCH1 expression in a subset of NOTCH1
Mutated T-
ALL samples (patients 08, 11) after treatment with hN1 mAb
(Figure 3D, **, P,0.01; *, P,0.05). One NOTCH1
Mutated sample
(patient 05) showed only a trend towards reduction in NOTCH1
expression after hN1 mAb treatment. However, this patient
harbored multiple additional mutations in other pathways
(Table 1) that could contribute to resistance of the LIC
population. Of note, one patient sample (patient 02) did not
harbor a NOTCH1 mutation, as determined by DNA sequenc-
ing (Table 1), but exhibited increased NOTCH1 transcript levels
(NOTCH1
High) compared to cord blood progenitors (Figure
S1C), as well as increased bone marrow serial transplantation
potential (Figure S4). Similar to the NOTCH1
Mutated samples, the
CD34
+ population of cells in the NOTCH1
High sample was
reduced following hN1 mAb treatment compared to control IgG.
Alternative NOTCH1 inhibitory strategies also recapitulated
the effects of antibody-mediated NOTCH1 pathway down-
regulation, as demonstrated by in vitro lentiviral NOTCH1 shRNA
knock down experiments (Figure S5). NOTCH1-shRNA treat-
ment of CD34
+ cells derived from NOTCH1
High (patient 02) or
NOTCH1
Mutated (patient 05) samples resulted in reduced expression
levels of NOTCH1 mRNA (Figure S5A) and downstream target
genes (c-MYC) (Figure S5B).
hN1 mAb Treatment Inhibits NOTCH1-Driven LIC Self-
renewal
Following hN1 mAb treatment, FACS analysis revealed a re-
duction in both the populations of CD45
+CD34
+ cells (Figure 4A,
upper panel) and immature T cells identified by CD34
+CD2
+
immunoreactivity (Figure 4A, lower panel) in NOTCH1
Mutated LIC
(Patient 11) engrafted mouse bone marrows, as well as a reduction
of the CD34
+NOTCH1
+ cell population in bone marrow and
spleen (Figure 4B). To determine whether hN1 mAb treatment
inhibited NOTCH1-driven LIC self-renewal, human CD34
+ cells
selected from the bone marrows of hN1 mAb (n=4) and IgG1
mAb (n=3) treated mice were serially transplanted into untreated
secondary (2u) recipients. After 12 weeks, FACS analysis showed
that mice transplanted with human CD34
+ T-ALL cells obtained
from control IgG1 mAb-treated mice exhibited higher
CD45
+CD34
+ leukemic burden compared to mice transplanted
with CD34
+ cells obtained from hN1 mAb-treated mice
(Figure 4C). Conversely, hN1 mAb-treated human T-ALL LIC
Figure 3. hN1 mAb treatment inhibits NOTCH1-driven LIC self-renewal. (A) Graph depicting average number of caspase 3 (red) and
NOTCH1 (blue) positive cells (mean 6 SEM), measured by marrow immunohistochemistry (cell number/randomized 406fields) following hN1 versus
control mAb treatment of T-ALL LIC (Patient 08) engrafted mice (**, P=0.005, *, P=0.046, respectively by two tailed Student’s t test with unequal
variance). (B) Immunoperoxidase analysis of human NOTCH1, human CD45 and human Caspase 3 expression in no transplant control (left panel),
compared with control mAb (middle panel) and hN1 mAb (right panel) treated NOTCH1
Mutated LIC (Patient 08) engrafted mice (406magnification).
(C) Following hN1 mAb treatment, immunoperoxidase staining of marrow sections was used to compare NOTCH1 intracellular domain (ICN1)
expression (Patient 08) in control mAb (left) and hN1mAb (right) treated mice (406magnification). (D) Quantitative RT-PCR assessment of relative
reduction in HPRT normalized NOTCH1 transcript levels in human CD34
+ cells derived from NOTCH1
Mutated (Patients 05, 08, 11) T-ALL LIC engrafted
bone marrows following hN1 mAb or control mAb treatment (**, P,0.01; *, P,0.05, Student’s t-test). All results reflect data collected from two
independent experiments.
doi:10.1371/journal.pone.0039725.g003
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+ cell
burden (Figure 4D; **, P=0.01, unequal variance two tailed
Student’s t-test) and the CD45
+CD34
+ leukemic cell population
(Figure 4D; *, P=0.05) in the 2u transplant recipients, indicating
that NOTCH1 inhibition abrogates T-ALL LIC self-renewal.
Although NOTCH1
Mutated T-ALL LIC demonstrated enhanced
leukemic engraftment capacity compared with NOTCH1
WT T-
ALL CD34
+ cells, the survival of NOTCH1
Mutated T-ALL LIC
appeared to be reliant on NOTCH1 signaling, thereby leading to
enhanced sensitivity to hN1 mAb inhibition in a niche-dependent
manner.
Enrichment of LIC in the CD45
+CD34
+CD2
+CD7
+
Population and Depletion Following hN1 Antibody
Treatment
Recent studies have highlighted the importance of CD7
expression in discriminating the LIC population in T-ALL
[10,36]. In this context, we hypothesized that early T cell markers
such as CD7 and CD2 might be enriched, and these populations
might be serially transplantable, in NOTCH1-driven T-ALL LIC
xenografted mice. While overall engraftment was similar between
NOTCH1
High and NOTCH1
Mutated transplanted samples (Figure 5A),
FACS analyses revealed an expansion of
CD45
+CD34
+CD2
+CD7
+ and CD45
+CD34
+CD2
+CD7
2 popu-
lations in NOTCH1
Mutated (patients 05, 08, 11, 12) and NOTCH1
High
(patient 02) T-ALL samples when compared with NOTCH1
WT
Figure 4. hN1 mAb treatment inhibits NOTCH1
Mutated LIC burden. (A) Comparative FACS analysis of human CD34
+CD45
+ cells and CD34
+CD2
+
leukemic burden in the bone marrows from NOTCH1
Mutated LIC (Patient 11) engrafted mice following treatment with control mAb (left panel) or hN1
mAb (right panel). (B) FACS analysis of human CD34
+ and NOTCH1
+ cell survival in the mouse spleens following control mAb (n=9) or hN1 mAb
treatment (n=9) of NOTCH1
Mutated LIC (Patients 05, 08, 11) engrafted mice (upper panel). Representative FACS plots show the reduction in both
CD34
+ and NOTCH1
+ cell populations. (C) Representative FACS analysis demonstrating engraftment of CD34
+CD45
+ cells in the bone marrows of
secondary (2u) transplant recipients following transplantation of control mAb (left panel) or hN1 mAb (right panel) treated bone marrow (Patient 11).
(D) Graph of percent human T-ALL total CD45
+ (blue) and CD34
+CD45
+ (red) cells in the bone marrows of 2u transplant recipients of control mAb
(n=6) and hN1 mAb (n=6) treated NOTCH1-driven LIC (Patients 02, 11) (error bars 6 SEM; P=0.16, and P=0.086, respectively, by Student’s t-test). All
results reflect data collected from two independent experiments.
doi:10.1371/journal.pone.0039725.g004
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Following serial transplantation of NOTCH1-activated LIC,
FACS analyses revealed that the CD45
+CD34
+CD2
+CD7
+
population harbored serial leukemic transplantation potential at
limiting doses (Table 2 and Figures 6A-C). To test our hypothesis
that the CD2
+CD7
+ subset of the CD34
+ human progenitor
population identifies a LIC-enriched population in NOTCH1
Mutated
T-ALL samples, CD34
+CD2
+CD7
+Lin
- cells from NOTCH1
Mutated
T-ALL samples (Patients 05 and 11) were FACS Aria purified and
serial transplantations were performed. Serial transplantation of 1
500 CD34
+CD2
+CD7
+Lin
2 cells sorted from a NOTCH1
Mutated T-
ALL (Patient 05) sample resulted in marked thymic enlargement,
splenomegaly and pale marrows indicative of robust leukemic
engraftment (Table 2 and Figure 6A). Tertiary transplant
experiments revealed that the human CD45
+CD34
+CD2
+CD7
+
population propagated leukemia and seeded hematopoietic niches,
which was demonstrative of LIC self-renewal capacity (Figures 6B
and C). As further evidence that this model recapitulates features
of the human disease, infiltration of human CD45
+ cells was
detected in the brains of mice that received 3u transplants of the
enriched LIC population (CD34
+CD2
+CD7
+) from patient 11
(Figure S6).
We then sought to determine whether this LIC-enriched
population was sensitive to hN1 antibody treatment. Remarkably,
compared to control mAb-treated animals transplanted with the
bulk CD34
+ population, in hN1 mAb-treated T-ALL LIC
engrafted mice, there was a significant reduction in the
CD34
+CD2
+CD7
+ population, but not the CD34
+CD2
+CD7
2
population (Figure 5C). Taken together, in NOTCH1
Mutated T-ALL
samples, a CD45
+CD34
+CD2
+CD7
+ population is enriched for
LIC that demonstrate serial leukemic transplantation capacity,
and these cells are selectively targeted and depleted by hN1
antibody therapy.
Discussion
Cumulative reports reveal the protean nature of NOTCH
signaling in the maintenance of normal and malignant hemato-
poiesis [13,24–27,37,38]. While Notch2 signaling regulates re-
generation of mouse long-term HSC, ligand-driven NOTCH1
activation induces human hematopoietic progenitor expansion
and differentiation [28,39]. Ligand binding to the NOTCH1
extracellular domain activates ADAM family metalloprotease and
c-secretase complex-mediated cleavage and intracellular release of
the NOTCH1 intracellular domain (ICN1). Subsequently, nuclear
translocation of ICN1 followed by engagement of transcriptional
activators such as CBF1/Su(H)/Lag2 (CSL) and mastermind-like
(MAML) sets the stage for NOTCH1 target gene transcription.
Conversely, activation of NOTCH1 signaling through gain-of-
function mutations in NOTCH1, first described in T-ALL [24], or
loss-of-function mutations in NOTCH1 regulators, such as FBXW7
and NUMB, has been linked to therapeutic recalcitrance of
hematologic malignancies [40,41]. Chronic antagonism of both
NOTCH1 and NOTCH2 processing with small molecule
inhibitors of the c-secretase complex has been associated with
loss of intestinal crypt progenitor cells, thereby providing the
impetus for development of selective NOTCH1 inhibitors [42].
Recent pre-clinical studies demonstrate that inhibition of
NOTCH1 using synthetic stapled peptides or monoclonal
antibody-mediated strategies effectively decreases T-ALL cell line
growth [22,23]. However, the consequences of selective NOTCH1
inhibition for normal hematopoietic progenitor and patient-
derived T-ALL LIC survival and self-renewal have been unclear.
In this study, CD34
+ cells from 6 of 12 T-ALL samples
harbored NOTCH1 activating mutations. In these patients,
NOTCH1
Mutated CD34
+ LIC had greater engraftment and serial
transplantation potential than their CD34
2 counterparts. Con-
versely, both CD34
+ and CD34
2 subpopulations from
NOTCH1
WT samples harbored roughly equivalent bioluminescent
engraftment potential, albeit at lower levels than NOTCH1
Mutated
LIC and with lower serial transplantation capacity. With the
exception of one sample (patient 02) that harbored high NOTCH1
transcript levels in the absence of identifiable NOTCH1 mutations,
bioluminescent imaging and FACS analyses of leukemic engraft-
ment suggest that phenotypic markers other than CD34 will be
needed to identify LIC in the NOTCH1
WT samples. In contrast to
experiments with NOTCH1
WT and normal cord blood CD34
+
samples, NOTCH1
Mutated LIC survival was significantly impaired by
selective hN1 mAb-mediated inhibition, concomitant with reduc-
tions in ICN1 and NOTCH1 mRNA expression and protein levels.
Furthermore, serial transplantation potential was also reduced by
hN1 mAb treatment of mice transplanted with NOTCH1-
activated T-ALL samples. Thus, NOTCH1
Mutated CD34
+ cells from
these pediatric T-ALL patients constitute the apex of a leukemic
hierarchy.
Notably, patient samples with NOTCH1 activation, conferred
either by mutation or elevated WT NOTCH1 expression levels,
show enrichment of a subset of the CD34
+ human progenitor cell
population distinguished by co-expression of CD2 and CD7.
Seminal studies reveal that CD7 expression enriches for a thera-
peutically recalcitrant LIC population [10,36]. Our analyses of the
serial transplantation capacity of the CD34
+CD2
+CD7
+ popula-
tion reveal that this population is maintained over multiple
generations of T-ALL LIC transplantation, and these cells harbor
robust leukemic initiating potential in medullary and extramedul-
lary reservoirs of resistance. In experiments aimed at elucidating
the fate of these cells in mice treated with hN1 mAb, we observed
a significant reduction in this population compared to animals that
received control IgG1 antibody. Taken together, these data further
refine the markers that identify LIC in NOTCH1
Mutated T-ALL
samples, and demonstrate that the CD34
+CD2
+CD7
+ population
is sensitive to and depleted following hN1 mAb treatment. While
in the present studies, our analyses of the refined LIC marker were
focused on the NOTCH1
Mutated samples, additional markers, or
activation of other receptor-mediated signaling pathways such as
insulin-like growth factor 1 receptor [43], may also be informative
to determine the leukemic potential of LIC in non-NOTCH1
Mutated
T-ALL patients.
While mutations in tumor suppressor genes co-exist in some
samples, NOTCH1
Mutated T-ALL LIC appear to be oncogenically
addicted to NOTCH1 activation, rendering them uniquely
susceptible to inhibition with a NOTCH1-targeted mAb, hN1.
In contrast, hN1 mAb treatment did not significantly impair the
survival of normal human hematopoietic progenitor cells. This
favorable therapeutic index may be explained, at least in part, by
mouse models of hematopoiesis, which demonstrate that Notch2,
rather than Notch1, regulates mouse HSC regeneration [30]. In
summary, characterization of LIC based on functional molecular
drivers provides a useful paradigm for identification and selective
elimination of malignant stem cells. Moreover, these findings
provide a compelling rationale for clinical evaluation of hN1 mAb
therapy in clinical trials aimed at eliminating self-renewing LIC
that promote therapeutic resistance and relapse in T-ALL and
potentially in other NOTCH1-driven malignancies.
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+CD34
+CD2
+CD7
+ population in NOTCH1
Mutated T-ALL LIC is sensitive to hN1 mAb treatment. (A) Total
human CD45
+ cells including CD34
+CD45
+ and CD34
-CD45
+ in secondary (2u) transplant recipients were summarized by graphing the results of CD45
FACS analysis. Human cord blood CD34
+ progenitors were used as a normal progenitor control, where the engraftment of human CD45
+ cells in bone
marrow was 7.13% 61.3 (n=6). (B) FACS analysis of pediatric T-ALL engrafted bone marrows revealed an expanded human CD45
+CD34
+CD2
+CD7
+
population in secondary (2u) transplant recipients that was more prominent in NOTCH1
Mutated T-ALL (Patient 05, n=9; Patient 08, n=8; Patient 11,
n=8; Patient 12, n=3) and NOTCH1
High T-ALL (Patient 02, n=10) transplanted mice than NOTCH1
WT T-ALL transplanted mice (Patient 09, n=4;
Patient 10, n=3). Human cord blood CD34
+ progenitors were used as a normal progenitor control (n=6). The CD34
+CD45
+, CD34
+CD45
+CD2
+CD7
+,
and CD34
+CD45
+CD2
+CD7
2 populations were significantly higher in the bone marrows of both NOTCH1
Mutated and NOTCH1
High T-ALL LIC
transplanted mice (**, P,0.01; ***, P,0.001, Student’s t test) when compared with NOTCH1
WT T-ALL LIC transplanted mice. (C) FACS analysis of
pediatric T-ALL LIC (Patient 05, n=5 in control group, n=6 in hN1 group; Patient 08, n=5 in control group, n=6 in hN1 group; Patient 11, n=4 in
control group, n=5 in hN1 group) engrafted bone marrows showing a reduction in the human CD45
+CD34
+CD2
+CD7
+ cell population following hN1
mAb treatment compared to control IgG1 mAb (***, P,0.001, Student’s t test).
doi:10.1371/journal.pone.0039725.g005
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Ethics Statement
Dr. Jamieson is the PI on an existing Institutional Review Board
(IRB) approval for tissue banking, entitled ‘‘Protocol 070678:
Permission to Collect Blood and/or Bone Specimens and/or
Tumor Samples and/or Saliva from Patients with Hematology
Problems for Research (Adult).’’ Approval was obtained from the
UCSD Human Research Protections Program. Consent is always
written, and clinical investigations were conducted according to
the principles expressed in the Declaration of Helsinki. The
Human Research Protections Program office assists researchers in
complying with federal, state and University policies regarding
experimentation involving human subjects, and oversees the
review and conduct of research conducted by federally registered
IRBs. This study was carried out in strict accordance with the
recommendations of the Institutional Animal Care and Use
Committee (IACUC) at the University of California, San Diego.
The protocol was approved by the Committee under Animal Use
Protocol Number S06015. All efforts were made to minimize
suffering.
Subjects and Samples
T-ALL patient samples were obtained from Moores Cancer
Center, University of California San Diego and Dana-Farber
Cancer Institute, Harvard Medical Schools. Patient consent forms
were required from all patients or their legal guardians (if minors)
for all samples collected for the study. At each collection site,
samples were obtained under Institutional Review Board (IRB)
approval. Peripheral blood mononuclear cells (PBMC) were
purified by Ficoll-Hypaque centrifugation prior to fluorescence-
activated cell sorting (FACS) analysis and viable cryopreservation
in liquid nitrogen. Patient age range was 2–23 and mean age was
11.3 years. Diagnostic samples included patients 1–11, while the
sample 12 was donated by a patient with relapsed T-ALL.
Diagnostic blast immunophenotypes were not available (N/A) for
2 of 12 patients. Treatment was performed according to protocol
COG 05-01 for 01 to 07; protocol COG 9404 for patients 8 to 10;
the Larson protocol for patient 11 and patient 12 received COG-
ALL043 treatment.
Bioluminescent Humanized T-ALL LIC Models
Methods required for establishment of bioluminescent LIC
models using lentivirus-luciferase transduced primary patient
samples in neonatal RAG2
2/2cc
2/2 mice were described pre-
viously [6]. All animal experiments were approved by the Animal
Experimental Committee of the University of California San
Diego and were performed according to NIH recommendations
for animal use.
Human CD34 Initiating Cell Isolation and
Immunophenotypic Analysis
Immunophenotypic analysis was performed on all samples
(FACSAria II system, BD Biosciences, Franklin Lakes, NJ).
Human CD34
+ cells were purified from T-ALL peripheral blood
using a CD34 MicroBead Kit (Miltenyi Biotec, Auburn, CA) and
CD34
+ cell purity was assessed by FACS. For FACS sorting,
mouse IgG1s conjugated to PE, FITC, or APC were used as
isotype controls (BD Biosciences). Human CD45, CD34, CD38,
CD2, and CD7 expression was assessed using anti-CD45-V450,
anti-CD34-APC, anti-CD38-PE-Cy7, anti-CD2-FITC and anti-
CD7-PE, respectively, together with a lineage cocktail including
PE-Cy5.5-conjugated antibodies against human CD4, CD8,
CD14, CD19 and CD56. All antibodies for cell sorting FACS
analysis were obtained from BD Biosciences. Propidium iodide (PI)
was used to exclude dead cells and at least 10000 events were
acquired for each sample.
Lentiviral Transduction and Transplantation
Approximately 50000 human CD34
+ and CD34
2 cells
derived from both NOTCH1
Mutated and NOTCH1
WT samples
(defined by DNA sequencing) were selected from T-ALL blood
or bone marrow with the aid of immunomagnetic beads or
FACSAria, and transduced with lentiviral luciferase which
effectively transduced an average of 15–25% of cells, as
measured by FACS (data not shown). Cells were transplanted
intrahepatically into RAG2
2/2cc
2/2 mice within 48 hours of
birth [6]. For NOTCH1 shRNA knock down experiments,
100000 CD34
+ cells selected from the T-ALL patient samples
and cord blood (All Cells, Emeryville, CA) were transduced with
lentiviral vectors expressing shRNA targeting human NOTCH1
(Dharmacon, Lafayette, CO).
Table 2. Niche-dependent LIC leukemic transplantation potential.
1u Transplant Engraftment 2u Transplant Engraftment 3u Transplant Engraftment
CD34
+ CD45
+ Cells CD34
+ CD45
+ Cells CD34
+ CD45
+ Cells
T-ALL LIC
T-ALL
Code
Cell #
Transplant (n) BM Spleen Thymus BM Spleen Thymus BM Spleen Thymus
CD34
+CD2
+CD7
+ 05 12610
3 (n=3) 19.961.0 7.760.9 3.360.6 6.760.3 0.660.1 37.863.1 N/A
CD34
+CD2
+CD7
+ 05 1.5610
3 (n=3) 70.162.8 37.469.6 50.266.6 7.161.3 2.760.9 5.862.7 2.561.4 3.562.8 0.560.1
CD34
+CD2
+CD7
2 05 1.5610
3 (n=3) 53.961.3 43.664.4 4.260.4 6.860.3 0.660.1 2.160.3 0.360.1 5.761.3 2.160.7
CD34
+CD2
+CD7
+ 11 30610
3 (n=3) N/A 11.766.6 9.363.3 2.361.2 10.968.1 11.365.9 11.164.1
CD34
+CD2
+CD7
2 03 1.0610
3 (n=1) 1.460.3 1.160.6 0.460.2 2.561.4 5.062.8 0.560.1 N/A
1000, 1500, 12000, and 30000 CD34
+CD2
+CD7
+Lin
- and CD34
+CD2
+CD7
-Lin
- cells were sorted from T-ALL patient samples (Patients 03, 05, 11) and transplanted into
neonatal immune deficient (RAG2
2/2cc
2/2) mice. Numbers of cells transplanted and numbers of mice for each primary (1u) transplant experiment are indicated in the
table, and results are reported as mean percentages 6 SEM. Serial transplantations were performed using 50000 bone marrow cells derived from the engrafted mice.
For secondary (2u) transplants, five experiments were performed with an average of 4.060.32 mice transplanted per experiment. For tertiary (3u) transplants, three
experiments were performed with an average of 4.060.58 mice transplanted per experiment.
doi:10.1371/journal.pone.0039725.t002
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39725Figure 6. Leukemia regenerative capacity of the CD45
+CD34
+CD2
+CD7
+ population. (A) Representative photographs of hematopoietic
organs following intrahepatic transplantation of 1 500 FACS purified CD34
+CD2
+CD7
+Lin
2 cells from a NOTCH1
Mutated T-ALL (Patient 05) sample
demonstrates serial transplantation potential of this refined LIC population, as shown by the presence of an enlarged thymus, spleen and pale
marrows over several transplantation generations. (B, C) FACS analysis of the tertiary (3u) transplant recipients of 30000 CD34
+CD2
+CD7
+Lin
2 cells
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Model
Humanized LIC and normal hematopoietic progenitor mouse
models were established by intrahepatic transplantation of neo-
natal RAG2
2/2cc
2/2 mice with lentiviral luciferase-transduced
CD34
+ progenitor cells from 12 T-ALL samples or normal cord
blood samples. Engraftment was monitored with the aid of an
IVIS 200 system (Caliper Life Sciences, Inc.). LIC mouse models
were dosed starting at 6 weeks of age with either NOTCH1 mAb
or IgG1 mAb control (both provided by Pfizer, Inc., La Jolla, CA)
at 10 mg/kg intraperitoneally every 4 days for an average of 6
doses. To test whether hN1 mAb treatment could eliminate LIC in
humanized T-ALL mouse models, mice were sacrificed one day
after the last dose. At this endpoint (approximately 10 weeks of
age) the majority of animals were sacrificed before the disease was
evident. Bone marrow, spleen, thymus and liver were collected
and processed for FACS analysis of human CD45, CD34, CD2,
CD7 and NOTCH1 expression. NOTCH1 FACS analysis was
performed using the same mAb as was used for treatment.
Immunohistochemistry was performed using antibodies against
NOTCH1 (1:50 dilution, Pfizer, Inc.), CD45 (1:100 dilution, Cell
Signaling, Danvers, MA), activated caspase 3 (1:50 dilution,
Abcam, Cambridge, MA), as well as NOTCH1 intracellular
domain (1:50 dilution, ICN1, Epitomics, Burlingame, CA) to
examine expression levels in bone marrow sections following
treatment with either control IgG1 mAb or hN1 mAb.
Statistical Analysis
All statistical tests were performed for two sided p values.
Continuous variables for each comparison group were assessed for
distribution through univariate statistics. If the assumption of
normal distribution could be supported, then the Student’s t-test
was performed for comparison of two samples with assessment of
equality of variance with an F statistic. If the assumption of normal
distribution was not supported, nonparametric testing was
performed with the two sample Wilcoxon test using the t
approximation for samples with N of less than 20.
Supporting Information
Figure S1 Self-renewing LIC activate NOTCH1. (A)
Graph of mean thymic weight (grams) in primary (1u, n=6) and
secondary (2u,n = 8 )NOTCH1
Mutated T-ALL LIC (CD34
+ cells)
transplant recipients compared with no transplant control mice
(n=4) (error bars 6 SEM. **, P,0.01, unequal variance two
tailed Student’s t test). (B) Graph of mean splenic weight (grams) in
1u (n=6) and 2u (n=8) T-ALL LIC (CD34
+ cells) transplant
recipients compared with no transplant control mice (n=4) (mean
6 SEM. ***, P,0.001, unequal variance two sided Student’s t
test). (C) Normalized NOTCH1 transcript levels to HPRT in
engrafted human CD34
+ cells following transplantation of
NOTCH1
Mutated T-ALL (Patients 03, 05, 08, 11), NOTCH1
High
T-ALL (Patient 02), and NOTCH1
WT T-ALL (Patient 09) samples
compared with normal human cord blood CD34
+ cells (**,
P,0.01; ***, P,0.001; unequal variance two tailed Student’s t
test). This experiment was repeated 3 times.
(PDF)
Figure S2 Anti Notch1-NRR mAb specifically inhibits
NOTCH1 receptor signaling and is well-tolerated in the
humanized T-ALL LIC mouse model. (A) Human
NOTCH1-negative regulatory region/Fc (N1-NRR) or
NOTCH2-NRR/Fc fusion protein (N2-NRR) expression plas-
mids were transiently transfected into Freestyle 293F cells
(Invitrogen). The supernatants were coated in 96-well ELISA
plates at 10 mg/mL. Purified hN1 mAb was added to the wells at
the indicated concentrations. Graph of mean O.D. 450 value in
ELISA binding assays demonstrates control mAb (blue) and anti-
NOTCH1-NRR (hN1, red) mAb specificity for human NOTCH1
receptor versus NOTCH2 receptor. (B) NOTCH1 luciferase
(NOTCH1+Luc) reporter assays utilized DLL4-coated plates.
Graph depicts (blue bars) mean luciferase activity in BSA, DLL4,
DLL4+control mAb and DLL4+ hN1 mAb (20 mg/mL) treated
wells (mean 6 SEM). (C) Mouse weight monitoring during dosing
time (from day 1 to day 21) demonstrates that hN1 mAb treatment
was well-tolerated in the engrafted mice (Control group, n=24;
hN1 mAb group, n=28 mice). No significant weight loss was
detected throughout the 3-week dosing period.
(PDF)
Figure S3 hN1 mAb treatment spares normal hemato-
poietic progenitors. (A) Representative FACS plots of human
CD34 and CD45 bone marrow engraftment in mice (n=6)
transplanted with 50 000 normal human CD34
+ cord blood cells
from 3 different donors and treated with control mAb or hN1
mAb. (B) Graph of percent human CD45
+ (blue) cells (error bars
6 SEM; P=0.16) and human CD34
+CD45
+ (red) cells (error bars
6 SEM; P=0.21) surviving in bone marrows of human cord
blood CD34
+ cells (from 3 different donors) transplanted mice
following intraperitoneal treatment with control mAb (10 mg/kg,
n=6) or hN1 mAb (10 mg/kg, n=6) every 4 days for 3 weeks.
(PDF)
Figure S4 hN1 mAb treatment inhibits NOTCH1
High
LIC self-renewal. (A) Graph of HPRT-normalized q-RT-PCR
results showing NOTCH1 transcript levels (blue bars) in normal
cord blood CD34
+ cells compared with engrafted T-ALL CD34
+
cells from serially transplanted LIC from a NOTCH1
High patient
sample (Patient 02). This experiment was repeated 3 times. (B)
Graph of percent human CD34
+ cell engraftment determined by
FACS analysis in marrow, spleen and thymus of secondary (2u)
transplant recipients of T-ALL NOTCH1
High LIC (Patient 02,
n=10). (C) Representative photographs depicting characteristics
of serially transplanted mouse bone marrows derived from control
mAb and hN1 mAb treated NOTCH1
High LIC engrafted mice
(Patient 02). (D) FACS analysis demonstrating CD34
+CD45
+ LIC
engraftment in bone marrow following serial transplantation of
control mAb and hN1 mAb treated NOTCH1
High LIC (Patient
02).
(PDF)
Figure S5 Human NOTCH1 shRNA inhibits NOTCH1
and downstream genes in T-ALL patient samples. (A)
Normalized NOTCH1 expression to HPRT in CD34
+ cells
derived from T-ALL patient samples (patient 02 and 05) after
treatment with NOTCH1-targeting shRNA expressed in a lentiviral
vector with an MOI of 90 (error bars 6 SEM, **, P,0.001 by
Student’s t-test). (B) HPRT-Normalized c-MYC expression (error
bars 6 SEM; *, P,0.01 by Student’s t-test). These experiments
were repeated 3 times.
(PDF)
sorted from a NOTCH1
Mutated T-ALL (Patient 11) revealed the persistence of an expanded human CD45
+CD34
+CD2
+ (including CD7
+ and CD7
2)
population in the transplanted mouse hematopoietic organs (bone marrow, spleen, thymus and liver).
doi:10.1371/journal.pone.0039725.g006
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PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e39725Figure S6 Human cell infiltration in the tertiary
CD34
+CD2
+CD7
+ cells transplanted mouse brain. 30
000 CD34
+CD38
+CD2
+CD7
+Lin
2 cells sorted from T-ALL
patient 11 with the aid of FACS were intrahepatically transplanted
into neonatal RAG2
2/2gc
2/2 mice, and serial transplantation
were done by 50 000 mouse BM cells. Tertiary transplanted
mouse brain was fixed in 4% PFA and 30% sucrose overnight,
separately, and then embedded in OCT for section with the
thickness of 16 mm. Mouse brain sections were stained with anti-
human CD45 antibody, mounted with prolong gold (Invitrogen).
Images were taken under the Fluoview FVi10 confocal microscope
(Olympus). (A) H & E staining of the mouse ventricular area. Scale
bar is 100 mm. (B) Human CD45 Immunostaining of no
transplant control mouse brain. DAPI detects the mouse cell
nuclei. Scale bar is 20 mm. (C) Human CD45 Immunostaining of
3u transplant mouse brain (patient 11). Pink cell surface staining
represents the human CD45, and the blue staining is the cell
nuclei. Scale bar is 20 mm.
(PDF)
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